A Study in Healthy Male Subjects to Investigate the Comparability of Pharmacokinetics of the Fixed-Dose Combination of Pertuzumab and Trastuzumab Administered Subcutaneously Using a Handheld Syringe or Using the On-Body Delivery System

NCT05275010 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

151

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Male Subjects

Interventions

DRUG: Fixed-Dose Combination of Pertuzumab and Trastuzumab SC (PH FDC SC)
DEVICE: Handheld Syringe with Hypodermic Needle
DEVICE: On-Body Delivery System

Sponsor

Hoffmann-La Roche